Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center

Table 2

Tumor marker responses after the neoadjuvant chemotherapy.

Items	Preneoadjuvant chemotherapy; (𝑛=23)	Postneoadjuvant chemotherapy; (𝑛=23)	𝑃 value*
CEA median (range)	0.84 (0.05–14.40)	0.70 (0.17–13.90)	0.030
CA125 median (range)	0.77 (0.25–14.26)	0.45 (0.19–6.28)	0.003
CA199 median (range)	0.24 (0.05–59.46)	0.20 (0.00–25.31)	0.005

∗The tumor markers were expressed as folds over upper normal limit. 𝑃 values for tumor markers were calculated using Wilcoxon test.
CEA: carcinoembryonic antigen; CA125: cancer antigen 125; CA199: carbohydrate antigen 199.